Genentech, Inc.

F. Hoffmann-la Roche Ag

Array Biopharma Inc.

Sugen Incorporated

Hoffmann-la Roche Inc.

Genetech, Inc.

Covenentech, Inc.

Steven Huy Do

Aleksandr Kolesnikov

Alan G Olivero

Adrian Folkes

Steven T Staben

Stephen Colin Price

Robert Andrew Heald

Chudi Obioma Ndubaku

Timothy Heffron

Nicole Blaquiere

Danette Dudley

Richard A Goldsmith

Lan Wang

Jun Liang

Mark Jones

James F Blake

Brian Salvatore Safina

Ian S Mitchell

Rui Xu

Dengming Xiao

Michael Siu

Birong Zhang

Keith Lee Spencer

Nicholas C Kallan

Josef R Bencsik

Christine Chabot

Bing-Yan Zhu

Daniel P Sutherlin

Tim Heffron

Tracy Bayliss

Neil Pegg

Paul Goldsmith

Eli M Wallace

Stephen T Schlachter

Jingrong Jean Cui

Xiaojing Wang

Sushant Malhotra

Marcel Koenig

Binqing Wei

Fang-Jie Zhang

Huiyong Hu

Peng Cho Tang

Wendy Lee

BinQing Wei

Chung Chen Wei

Vickie H Tsui

Naomi S Rajapaksa

Xiaoyuan Li

Hong Shen

Marian C Bryan

Anna L Banka

Zhaoyang Wen

James Richard Kiefer, Jr

Jack Alexander Terrett

Ji Yu Chu

Liqiang Fu

Tamiko Katsumoto

Ruofei Zhang

Jianfeng Xin

Joseph P Lyssikatos

Fei Wang

Anthony A Estrada

Huifen Chen

Congxin Liang

Lewis J Gazzard

Vickie Hsiao-Wei Tsui

Po-Wai Yuen

Vishal Verma

Ping Huang

Elisia Villemure

Kwong Wah Lai

Daniel Shore

Guosheng Wu

Tomas Vojkovsky

Joy Drobnick

Yamin Zhang

Aijun Lu

Alberto Gobbi

Zhiguo Liu

Baihua Hu

John Wai

Yongsheng Chen

James M Graham

Xingyu Lin

Samantha Alyson Green

Yanyan Chu

Anna L Leivers

Cheng Shao

Matthew Leo Landry

Christian Nilewski

Matthew Volgraf

Jack Terrett

Adrian J Folkes

Eli W Wallace

Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

Aza-tetracyclic oxazepine compounds and uses thereof

This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

Fused ring compounds

Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

Compounds having the formula I wherein R, X, X, Xand Xas defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Serine/threonine kinase inhibitors

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

IRAK4 modulators

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazolo[3,4-c]pyridine compounds and methods of use

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin PI3K inhibitor compounds and methods of use

Growing community of inventors

San Jose, CA, United States of America

Steven Huy Do